The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Quest Diagnostics's revenues will compress -3.6% and EPS will decrease -6.8%.
The average estimate for revenue is $1.84 billion. On the bottom line, the average EPS estimate is $1.09.
Last quarter, Quest Diagnostics reported revenue of $1.79 billion. GAAP reported sales were 6.4% lower than the prior-year quarter's $1.91 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.89. GAAP EPS of $0.85 for Q1 were 14% lower than the prior-year quarter's $0.99 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 39.9%, 200 basis points worse than the prior-year quarter. Operating margin was 15.2%, 40 basis points worse than the prior-year quarter. Net margin was 7.6%, 70 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $7.31 billion. The average EPS estimate is $4.35.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 556 members out of 592 rating the stock outperform, and 36 members rating it underperform. Among 201 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 190 give Quest Diagnostics a green thumbs-up, and 11 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Quest Diagnostics is hold, with an average price target of $59.97.
Is Quest Diagnostics the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Quest Diagnostics to My Watchlist.